Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) announced a dividend on Tuesday, May 20th, investing.com reports. Shareholders of record on Friday, May 23rd will be given a dividend of 0.43 per share on Monday, June 30th. This represents a yield of 13.82%. The ex-dividend date is Thursday, May 22nd.
Abrdn Life Sciences Investors Trading Up 1.1%
Abrdn Life Sciences Investors stock opened at $12.46 on Tuesday. The business's 50-day simple moving average is $12.28 and its two-hundred day simple moving average is $13.31. Abrdn Life Sciences Investors has a fifty-two week low of $10.55 and a fifty-two week high of $15.90.
Insider Activity
In related news, major shareholder Saba Capital Management, L.P. sold 48,623 shares of the company's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $12.58, for a total value of $611,677.34. Following the completion of the transaction, the insider now owns 3,188,405 shares of the company's stock, valued at approximately $40,110,134.90. This represents a 1.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 198,861 shares of company stock valued at $2,422,653 in the last quarter. 10.06% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Abrdn Life Sciences Investors
An institutional investor recently raised its position in Abrdn Life Sciences Investors stock. NewEdge Advisors LLC grew its stake in Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 43.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,500 shares of the company's stock after purchasing an additional 9,785 shares during the period. NewEdge Advisors LLC owned approximately 0.11% of Abrdn Life Sciences Investors worth $412,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 32.21% of the stock is currently owned by institutional investors and hedge funds.
Abrdn Life Sciences Investors Company Profile
(
Get Free Report)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abrdn Life Sciences Investors, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abrdn Life Sciences Investors wasn't on the list.
While Abrdn Life Sciences Investors currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
